Successful augmentation of clozapine-resistant treatment of schizophrenia with clonidine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 4, 2010, Pages 724-725

  Dardennes, Roland M ^a,b,c,d   Al Anbar, Nebal N ^d   Rouillon, Frédéric ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^d 9 Quai Saint Bernard   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLONIDINE; CLOZAPINE; HALOPERIDOL; HALOPERIDOL DECANOATE; OLANZAPINE;

ADJUVANT THERAPY; ADULT; AUDITORY HALLUCINATION; CASE REPORT; DELUSION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERSALIVATION; LETTER; MALE; SCHIZOPHRENIA; SYMPTOM; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADRENERGIC ALPHA-AGONISTS; ADULT; CLONIDINE; HUMANS; MALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77952671973     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.03.022     Document Type: Letter

References (12)

1. Arnsten A.F.T. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology 2004, 174:25-31.
2. Hoffman R.E., Hawkins K.A., Gueorguieva R., Boutros N.N., Rachid F., Carroll K., et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch Gen Psychiatry 2003, 55:49-56.
3. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
4. Lechin F., van der Dijs B., Gomez F., Valls J.M., Acosta E., Arocha L. Pharmacomanometric studies of colonic motility as a guide to the chemotherapy of schizophrenia. J Clin Pharmacol 1980, 20:664-671.
5. Lerner A.G., Finkel B., Oyffe I., Merenzon I., Sigal M. Clonidine treatment for hallucinogen persisting perception disorder. Am J Psychiatry 1998, 155:1460.
6. Litman R.E., Su T.P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 1996, 168:571-579.
7. Meltzer H.Y., Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008, 172:177-197.
8. Mouaffak F., Tranulis C., Gourevitch R., Poirier M.F., Douki S., Olié J.P., et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol 2006, 29:28-33.
9. Praharaj S.K., Verma P., Roy D., Singh A. Is clonidine useful for treatment of clozapine-induced sialorrhea?. J Psychopharmacol 2005, 19:426-428.
10. Sadock B.J., Sadock V.A. Kaplan & Sadock's pocket handbook of psychiatric treatment 2001, Lippincott Williams & Wilkins, Philadelphia. 3rd ed.
11. Tollefson G.D., Birkett M.A., Kiesler G.M., Wood A.J. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001, 49:52-63. Lilly Resistant Schizophrenia Study Group.
12. Yamamoto K., Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:913-922.